Combination treatment for acute heart failure with diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether a combination of a diabetes pill (SGLT-2 inhibitor) and a strong water pill (furosemide) with a small amount of salt water can help people with acute heart failure and type 2 diabetes feel better faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute heart failure (a sudden worsening of heart failure symptoms).
- You have type 2 diabetes.
- Your kidney function is not too low (your doctor will check a blood test).
- Your blood sodium level is not too high (your doctor will check).
- You have not had a heart attack or recent heart-related emergency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different water pills (acetazolamide and metolazone) added to standard care for people hospitalized with acute heart failure who still have fluid buildup after an initial dose of IV furosemide. The goal is to see which works better to remove extra fluid.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.
This trial tests if dapagliflozin or acetazolamide works better for people hospitalized with heart failure who have extra fluid in their body (congestion). The study will compare how well each medication helps remove fluid when used with standard IV diuretics.
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.